TNFRSF17 and plasma cell myeloma: The analysis showed that BCMA, ICAM3 (CD50), CD221, and CS1 (SLAMF7) are the most abundantly expressed markers at all stages of myeloma, with BCMA, ICAM3, and CD221 being expressed at significantly higher levels in diseased rather than precursor PCs.